---
title: "Protagonist Therapeutics Announces Presentation of Icotrokinra Phase 2b Trial Results at United European Gastroenterology Week 2025"
description: "Protagonist Therapeutics, Inc. announced that results from the Phase 2b ANTHEM-UC study of icotrokinra for ulcerative colitis will be presented at the United European Gastroenterology Week 2025 in Ber"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/257400179.md"
published_at: "2025-09-15T14:45:21.000Z"
---

# Protagonist Therapeutics Announces Presentation of Icotrokinra Phase 2b Trial Results at United European Gastroenterology Week 2025

> Protagonist Therapeutics, Inc. announced that results from the Phase 2b ANTHEM-UC study of icotrokinra for ulcerative colitis will be presented at the United European Gastroenterology Week 2025 in Berlin on October 7, 2025. The presentation will cover Week 12 results from this randomized, double-blind, placebo-controlled study, focusing on icotrokinra's effects on patients with moderately to severely active ulcerative colitis. Dr. Maria Abreu from Cedars-Sinai Medical Center will deliver the presentation.

Protagonist Therapeutics, Inc. has announced that data from the Phase 2b ANTHEM-UC study involving the drug icotrokinra for the treatment of ulcerative colitis will be the subject of an oral presentation at the upcoming United European Gastroenterology Week 2025 in Berlin, Germany. The presentation, scheduled for October 7, 2025, will focus on the Week 12 results of the trial, which is a randomized, double-blind, placebo-controlled, dose-ranging study. The study evaluates icotrokinra, a targeted oral peptide that selectively blocks IL-23 receptor activation, in patients with moderately to severely active ulcerative colitis. The presentation will be delivered by Dr. Maria Abreu from Cedars-Sinai Medical Center, and abstracts are currently available on the UEGW website. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073229) on September 15, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [PTGX.US - Protagonist Therap](https://longbridge.com/en/quote/PTGX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 正在推進的、風險已降低的研發管線以及短期監管催化劑支撐 Protagonist 治療的買入評級 | Wedbush 的分析師 Yun Zhong 維持了對 Protagonist Therapeutics 的買入評級，目標價為 86.00 美元，理由是該公司的管線進展順利，主要資產 rusfertide 的風險已降低。針對多發性紅細胞增多 | [Link](https://longbridge.com/en/news/271699145.md) |
| GSK 的 Exdensur 在歐盟獲批用於重度哮喘和慢性鼻竇炎的附加治療 | GSK 的 Exdensur 在歐盟獲得批准，作為重度哮喘和慢性鼻竇炎的輔助治療 | [Link](https://longbridge.com/en/news/276103226.md) |
| 以「仁心、安心、貼您心」實踐 ESG   仁安醫院推動綠色醫療與社區共融 | 仁安醫院自 1995 年成立以來，秉承「仁心、安心、貼您心」的核心價值，致力於提供優質醫療服務並推動可持續發展。醫院將環境、社會與企業管治視為長期發展支柱，通過制度化管理與社區參與落實「綠色醫療」。醫院重視人才培養與企業文化，積極參與醫療認 | [Link](https://longbridge.com/en/news/274898676.md) |
| 禮來公司聲明：Mirikizumab 在中國獲批用於治療中度至重度克羅恩病和潰瘍性結腸炎 | 禮來：Mirikizumab 在中國獲得批准用於治療中重度克羅恩病和潰瘍性結腸炎 - 公司聲明 | [Link](https://longbridge.com/en/news/275551012.md) |
| Molina 醫療｜10-K：2025 財年營收 454 億美元 |  | [Link](https://longbridge.com/en/news/275512865.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.